Tevogen develops AI model to accelerate immunotherapy research

Tevogen Bio Holdings Inc. (NASDAQ: TVGN) announced it has developed the alpha version of PredicTcell™, a machine learning model created in collaboration with Microsoft Corp. (NASDAQ: MSFT) and Databricks, according to a company statement.

The Warren, New Jersey-based company said the model reduces target analysis time in immunotherapy research by weeks and could potentially save billions in drug development costs. The announcement came as the company expressed support for the White House's "Winning the Race: America's AI Action Plan" released July 23.

The AI Action Plan emphasizes establishing domain-specific standards, regulatory sandboxes, and stakeholder convenings led by The National Institute of Standards and Technology to build trust, governance, and productivity in healthcare AI.

"As a mission-driven innovator, Tevogen.AI believes that AI has the potential to significantly reduce the cost and time required to bring life-saving treatments to patients in need," said Ryan Saadi, the company's founder and CEO. "We commend the U.S. government for recognizing this potential and setting a national strategy."

The company stated its work focuses on developing scalable, ethical solutions that expand access to affordable, advanced therapeutics. Tevogen operates in the biopharmaceutical sector, developing treatments for infectious diseases and cancer.

You May Also Be Interested In

• First Advantage to join S&P SmallCap 600, replacing Kennedy-Wilson
• Copa Holdings reports 17% increase in May passenger traffic
• Sonida Senior Living (SNDA) files for 17.11M share offering by selling stockholders